在初治的具有表皮生长因子受体（EGFR）敏感突变的非小细胞肺癌（NSCLC）中T790M检测率高：是事实还是假象？ - Suppr

Suppr

超能文献

High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?

作者信息

Ye Xin, Zhu Zhong-Zheng, Zhong Lei, Lu Yachao, Sun Yun, Yin Xiaolu, Yang Zhenfan, Zhu Guanshan, Ji Qunsheng

机构信息

Innovation Center China of AstraZeneca Research & Development, Shanghai, China.

出版信息

J Thorac Oncol. 2013 Sep;8(9):1118-20. doi: 10.1097/JTO.0b013e31829f691f.

DOI:10.1097/JTO.0b013e31829f691f

PMID:23945382

Abstract

摘要

相似文献

High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?在初治的具有表皮生长因子受体（EGFR）敏感突变的非小细胞肺癌（NSCLC）中T790M检测率高：是事实还是假象？

J Thorac Oncol. 2013 Sep;8(9):1118-20. doi: 10.1097/JTO.0b013e31829f691f.

Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.EGFR 突变型非小细胞肺癌患者（序贯）再活检中 T790M 突变的发生率。

Lung Cancer. 2014 Jul;85(1):19-24. doi: 10.1016/j.lungcan.2014.03.016. Epub 2014 Mar 23.

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.治疗前表皮生长因子受体 (EGFR) T790M 突变可预测非小细胞肺癌患者对 EGFR 酪氨酸激酶抑制剂反应持续时间更短。

J Clin Oncol. 2012 Feb 1;30(4):433-40. doi: 10.1200/JCO.2011.38.3224. Epub 2012 Jan 3.

Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.高敏非侵入性检测非小细胞肺癌中表皮生长因子受体 T790M 突变。

Clin Chim Acta. 2013 Oct 21;425:119-24. doi: 10.1016/j.cca.2013.07.012. Epub 2013 Jul 23.

T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.T790M 突变与晚期 NSCLC 患者在 EGFR-TKI 治疗进展后更好的疗效相关。

Lung Cancer. 2014 Jun;84(3):295-300. doi: 10.1016/j.lungcan.2014.03.011. Epub 2014 Mar 15.

Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.表皮生长因子受体酪氨酸激酶抑制剂获得性耐药的非小细胞肺癌患者的再次活检：T790M 突变阳性和突变阴性人群的比较。

Cancer. 2013 Dec 15;119(24):4325-32. doi: 10.1002/cncr.28364. Epub 2013 Sep 16.

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）联合贝伐单抗用于表皮生长因子受体（EGFR）突变的非小细胞肺癌的再挑战治疗

Cancer Chemother Pharmacol. 2015 Oct;76(4):835-41. doi: 10.1007/s00280-015-2867-8. Epub 2015 Sep 8.

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.表皮生长因子受体酪氨酸激酶抑制剂治疗作为 EGFR 突变的晚期非小细胞肺癌的一线治疗是有效的：来自六项 III 期随机对照试验的荟萃分析。

Int J Cancer. 2012 Sep 1;131(5):E822-9. doi: 10.1002/ijc.27396. Epub 2012 Jan 27.

Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.β-连环蛋白抑制增强了 T790M 突变的 EGFR 突变型非小细胞肺癌中不可逆 EGFR-TKI 的抗癌作用。

J Thorac Oncol. 2015 Jan;10(1):93-101. doi: 10.1097/JTO.0000000000000353.

Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.EGFR突变型肺癌中散发性原发性EGFR T790M突变的临床可能性

Clin Lung Cancer. 2015 Jan;16(1):46-50. doi: 10.1016/j.cllc.2014.09.002. Epub 2014 Sep 28.

引用本文的文献

Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials.利用循环肿瘤DNA（ctDNA）发现转移性非小细胞肺癌（NSCLC）患者对靶向治疗的耐药机制：迈向更具信息量的试验。

Nat Rev Clin Oncol. 2025 May;22(5):371-378. doi: 10.1038/s41571-025-01011-3. Epub 2025 Mar 14.

Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer.靶向PRMT1可降低EGFR和KRAS突变型肺癌的癌症持续性和肿瘤复发率。

Cancer Res Commun. 2025 Jan 1;5(1):119-127. doi: 10.1158/2767-9764.CRC-24-0389.

Targeting therapy-persistent residual disease.靶向治疗后残留病灶。

Nat Cancer. 2024 Sep;5(9):1298-1304. doi: 10.1038/s43018-024-00819-9. Epub 2024 Sep 17.

Large-scale analysis of whole genome sequencing data from formalin-fixed paraffin-embedded cancer specimens demonstrates preservation of clinical utility.从福尔马林固定石蜡包埋的癌症标本中进行全基因组测序数据的大规模分析证明了其临床实用性得以保留。

Nat Commun. 2024 Sep 4;15(1):7731. doi: 10.1038/s41467-024-51577-2.

Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.Oncomine Dx 靶标检测与 AmoyDx 试剂盒在检测肺癌可操作突变中的诊断性能比较。

Sci Rep. 2024 May 30;14(1):12480. doi: 10.1038/s41598-024-62857-8.

Targeting drug-tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells.靶向耐药细胞：克服癌细胞获得性耐药的一种有前景的策略。

MedComm (2020). 2023 Aug 24;4(5):e342. doi: 10.1002/mco2.342. eCollection 2023 Oct.

Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation.病例报告：伴有胚系表皮生长因子受体（EGFR）T790M突变的神经内分泌性乳腺癌

Front Oncol. 2023 May 17;13:1176868. doi: 10.3389/fonc.2023.1176868. eCollection 2023.

Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for -Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients.用于检测非小细胞肺癌患者预处理 FFPE 样本和液体活检中 -Thr790Met 突变的超高敏 PCR 方法的技术验证和临床意义。

Int J Mol Sci. 2022 Jul 31;23(15):8526. doi: 10.3390/ijms23158526.

Different Clinicopathologic and Computed Tomography Imaging Characteristics of Primary and Acquired Mutations in Patients with Non-Small-Cell Lung Cancer.非小细胞肺癌患者原发性和获得性突变的不同临床病理及计算机断层扫描成像特征

Cancer Manag Res. 2021 Aug 13;13:6389-6401. doi: 10.2147/CMAR.S323972. eCollection 2021.

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer.癌症中靶向治疗耐受持久性细胞的新见解

Cancers (Basel). 2021 May 28;13(11):2666. doi: 10.3390/cancers13112666.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验